Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $43.80.

Several research analysts have recently issued reports on the stock. Piper Sandler reiterated a "neutral" rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 11th. StockNews.com cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, October 23rd. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Friday. Finally, Needham & Company LLC raised shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective on the stock in a research report on Friday.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds have recently made changes to their positions in COLL. GAMMA Investing LLC increased its position in shares of Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock valued at $55,000 after acquiring an additional 792 shares during the period. CWM LLC lifted its stake in shares of Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock worth $58,000 after buying an additional 736 shares in the last quarter. TD Private Client Wealth LLC lifted its stake in shares of Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock worth $66,000 after buying an additional 483 shares in the last quarter. Virtus Fund Advisers LLC purchased a new position in shares of Collegium Pharmaceutical during the third quarter valued at approximately $72,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Collegium Pharmaceutical by 61.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 6,196 shares of the specialty pharmaceutical company's stock valued at $239,000 after purchasing an additional 2,352 shares during the last quarter.

Collegium Pharmaceutical Price Performance

COLL traded up $0.88 during trading on Monday, hitting $33.79. 421,351 shares of the stock traded hands, compared to its average volume of 593,934. Collegium Pharmaceutical has a twelve month low of $28.39 and a twelve month high of $42.29. The company has a market cap of $1.09 billion, a price-to-earnings ratio of 14.56 and a beta of 0.82. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The business has a 50 day moving average price of $30.56 and a 200 day moving average price of $34.08.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.